Background: Pruritus affects up to 80% of patients with primary biliary cholangitis (PBC) and reduces health-related quality of life (HRQoL). GLIMMER (NCT02966834) was a randomized, placebo-controlled phase IIb study of linerixibat in patients with PBC and pruritus. Using patient-reported outcome data from GLIMMER, we characterize the impact of pruritus in PBC.
Methods: To objectively assess HRQoL impact, EQ-5D-5L data from GLIMMER (0-1 scale; 0 = death, 1 = perfect health) were analyzed post-hoc across pruritus severities. Inter-relationships between pruritus severity (0-10 numerical rating scale [NRS]), depression (Beck Depression Inventory-II, post-hoc), and sleep interference (0-10 NRS) and their impact on HRQoL were explored.
Results: In patients with PBC (n = 147), severe pruritus was associated with worse HRQoL. EQ-5D-5L scores were lower in those with severe pruritus (≥7-10 NRS) versus mild/moderate pruritus (mean [SD]: 0.49 [0.28] and 0.75 [0.17]/0.76 [0.17], respectively). Among patients with severe pruritus, 31% had severe depression, versus 9/3% with mild/moderate pruritus. Patients with both severe pruritus and depression had a mean EQ-5D-5L score of 0.30. In those with severe pruritus, 54% reported severe sleep interference. Improvements in pruritus were accompanied by stepwise improvements in EQ-5D-5L scores.
Conclusions: This analysis of patients in the largest investigational trial of cholestatic pruritus to date shows a clear association between pruritus and impaired HRQoL. Patients with severe pruritus had HRQoL comparable to patients with severe Parkinson's disease. Severe pruritus alongside depression was associated with extremely poor HRQoL, indicating the importance of evaluating itch and managing depression. Sleep interference appears to be a major cofactor for reduced HRQoL. For each 1-point improvement in NRS HRQoL improved, clinicians should offer appropriate and timely intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11841849 | PMC |
| http://dx.doi.org/10.1097/HC9.0000000000000635 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroichthyosis With a De Novo Variant c.494C>T in ELOVL1 and Severe Pruritus Relieved by Dupilumab.
Pediatr Dermatol
March 2025
Faculty of Medicine, University of Montreal, Quebec, Canada.
We report a patient with neuroichthyosis with an ELOVL1 variant associated with severe pruritus who responded well to dupilumab therapy. Our case is the third known patient reported with this de novo heterozygous dominant variant. The feature of severe progressive pruritus greatly impairing quality of life is unique among these reports.
View Article and Find Full Text PDFExploring Immune-Related Biomarkers in Human Itch.
Dermatitis
March 2025
Dr. Phillip Frost Dept of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, Coral Gables, FL, USA.
Itch is a debilitating symptom that affects ∼40% of the population and significantly impacts patients' quality of life. The management of chronic itch remains a significant challenge due to the limited availability of reliable biomarkers for assessing its severity. This review aims to investigate the key neuroimmune-related biomarkers involved in the pathophysiology of itch and itch-dependent diseases.
View Article and Find Full Text PDFPityriasis Rubra Pilaris Following COVID-19 Infection: A Case of Successful Treatment With Ixekizumab.
Cureus
February 2025
Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Pityriasis rubra pilaris (PRP) is a rare dermatologic disorder marked by erythema, scaling, pruritus, pain, and follicular hyperkeratosis. It usually appears as red, scaly patches with areas of unaffected skin and is commonly associated with orange-colored palms and soles. While the exact etiology is unknown, emerging evidence points to several contributing factors.
View Article and Find Full Text PDFSkin Microbiome, Inflammation, and Skin Toxicities in Women with Breast Cancer Receiving Moderately Hypofractionated Radiation Therapy.
Int J Radiat Oncol Biol Phys
March 2025
Winship Cancer Institute, Emory University, Atlanta, GA; Department of Radiation Oncology, School of Medicine, Emory University, Atlanta, GA. Electronic address:
Purpose: Up to 95% of women during and after radiation therapy (RT) for breast cancer have reported cutaneous toxicity. However, the biologic link between skin microbiome and skin toxicities from RT remains largely unknown. This study aimed to assess the associations of skin microbiome with clinician- and patient-reported skin toxicities and inflammatory markers in women with breast cancer receiving RT.
View Article and Find Full Text PDFEfficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.
Dermatol Ther (Heidelb)
March 2025
Department of Dermatology, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease. 611, a humanized monoclonal antibody, selectively targets the interleukin (IL)-4 receptor alpha, thereby inhibiting the signaling of both interleukin (IL)-4 and IL-13. This phase 2 study aimed to evaluate the efficacy and safety of 611 in Chinese adults with moderate-to-severe AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!